1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Kidney conditions
  5. Chronic kidney disease

Sparsentan for treating primary IgA nephropathy [ID6308]

In development [GID-TA11359] Expected publication date: 25 June 2025

  • Project information
  • Project documents

Documents

A list of downloadable documents created during development.

Final draft guidance

  • Final draft guidance  
  • Final draft guidance PDF 252 KB 23 May 2025  
  • Committee papers PDF 1.3 MB 23 May 2025  
  • Public committee slides PDF 342 KB 23 May 2025  
  • Equality impact assessment (downloadable version) PDF 312 KB 23 May 2025  

Draft guidance

  • Draft guidance  
  • Committee papers PDF 10.39 MB 04 March 2025  
  • Public committee slides PDF 744 KB 04 March 2025  
  • Equality impact assessment (downloadable version) PDF 98 KB 04 March 2025  
  • Draft consultation document (downloadable version) PDF 294 KB 04 March 2025  
  • Draft guidance (online commenting)  

Declaration of interests

  • Register of interests PDF 104 KB 14 May 2025  

Invitation to participate

  • Final scope PDF 167 KB 05 March 2024  
  • Final stakeholder list PDF 179 KB 05 March 2024  
  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 121 KB 05 March 2024  
  • Equality Impact Assessment (Guidance development) PDF 144 KB 05 March 2024  

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6308

  • Draft scope post referral PDF 172 KB 15 September 2023  
  • Draft matrix post referral PDF 168 KB 15 September 2023